139 related articles for article (PubMed ID: 21981734)
1. Medical therapy for primary sclerosing cholangitis.
Wong GL; Wong VW
Aliment Pharmacol Ther; 2011 Nov; 34(9):1135-6; discussion 1136-7. PubMed ID: 21981734
[No Abstract] [Full Text] [Related]
2. Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid.
Chapman RW
Dig Liver Dis; 2003 May; 35(5):306-8. PubMed ID: 12846401
[No Abstract] [Full Text] [Related]
3. Commentary: ursodeoxycholic acid as chemoprevention in inflammatory bowel disease and primary sclerosing cholangitis.
Santander C; Moreno-Otero R
Aliment Pharmacol Ther; 2012 Apr; 35(7):846; discussion 847. PubMed ID: 22404405
[No Abstract] [Full Text] [Related]
4. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?).
Tabibian JH; Lindor KD
Hepatology; 2014 Sep; 60(3):785-8. PubMed ID: 24752961
[No Abstract] [Full Text] [Related]
5. Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?
Chapman RW
Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):74-5. PubMed ID: 20134486
[No Abstract] [Full Text] [Related]
6. [Primary sclerosing cholangitis. To slow progression and reduce carcinoma risk].
MMW Fortschr Med; 2006 Jun; 148(24):42-3. PubMed ID: 16850808
[No Abstract] [Full Text] [Related]
7. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
8. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.
Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M
Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404
[TBL] [Abstract][Full Text] [Related]
9. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
10. Ulcerative colitis and an abnormal cholangiogram.
Nguyen DL; Lazaridis KN
Cleve Clin J Med; 2011 May; 78(5):306-11. PubMed ID: 21536825
[No Abstract] [Full Text] [Related]
11. Treatment of primary sclerosing cholangitis.
Floreani A; De Martin S
Dig Liver Dis; 2021 Dec; 53(12):1531-1538. PubMed ID: 34011480
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
Stiehl A
Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and medical therapy of primary sclerosing cholangitis.
van Milligen de Wit AW
Eur J Gastroenterol Hepatol; 1999 Aug; 11(8):940. PubMed ID: 10514135
[No Abstract] [Full Text] [Related]
14. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2-year period.
De Maria N; Colantoni A; Rosenbloom E; Van Thiel DH
Hepatogastroenterology; 1996; 43(12):1472-9. PubMed ID: 8975951
[TBL] [Abstract][Full Text] [Related]
15. Ursodeoxycholic acid in primary sclerosing cholangitis.
Triantos CK; Koukias N; Nikolopoulou V; Burroughs AK
Aliment Pharmacol Ther; 2012 Mar; 35(5):622-3. PubMed ID: 22300127
[No Abstract] [Full Text] [Related]
16. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
17. [Ischemic cholangitis in intensive care unit: favourable outcome with ursodesoxycholic acid and fenofibrate].
Bélénotti P; Guervilly C; Grandval P; Benyamine A; Ene N; Serratrice J; Petit P; Laugier R; Papazian L; Weiller PJ
Rev Med Interne; 2013 Feb; 34(2):110-3. PubMed ID: 23200798
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis: A Human Pilot Study.
Assis DN; Abdelghany O; Cai SY; Gossard AA; Eaton JE; Keach JC; Deng Y; Setchell KD; Ciarleglio M; Lindor KD; Boyer JL
J Clin Gastroenterol; 2017 Feb; 51(2):e11-e16. PubMed ID: 27428727
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
20. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
